Filtered By:
Specialty: Pharmaceuticals
Drug: Niaspan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Trials Of Niacin And Atrial Fibrillation Device Will Headline American College Of Cardiology Program
Two big trials will highlight this year's American College of Cardiology meeting in March in San Francisco. First is the PREVAIL trial testing Boston Scientific's long-anticipated Watchman left atrial appendage closure device for stroke prevention in patients with atrial fibrillation. Second is the detailed presentation of the controversial failed HPS2-THRIVE trial of extended-release niacin and laropiprant. The final list of trials has been posted on the ACC website.
Source: Forbes.com Healthcare News - January 22, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
